Skip to main content
. 2019 Sep 27;98(39):e17216. doi: 10.1097/MD.0000000000017216

Figure 3.

Figure 3

The mRNA LTBP2 expression in patients with HCC according to clinicopathologic characteristics. (A) LTBP2 mRNA expression in patients with HCC, high grade DNs (n = 20), LC (n = 20) and CHB (n = 20) and normal controls (n = 60); (B) LTBP2 mRNA in HCC patients with well (n = 15), moderately (n = 18) and poorly (n = 27) differentiated tumors; (C) LTBP2 mRNA in HCC patients with tumor size >3 cm (n = 25) and ≤3 cm (n = 35); (D) LTBP2 mRNA in HCC patients at TNM stage I/II (n = 34) or III/IV (n = 26); (E) LTBP2 mRNA in HCC patients with no hepatitis virus infection (n = 11), HBV infection (n = 34) and HCV infection (n = 15). ∗∗P < .01. DNs = dysplastic nodules, CHB = chronic hepatitis B, HCA = hepatocellular adenoma, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, LC = liver cirrhosis, LTBP2 = latent TGF-β binding protein 2, mRNA = messenger RNA, TNM = tumor–node-metastasis.